- Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Phase 3 Randomized, Multicenter Study of Subcutaneous Daratumumab Versus Active Monitoring in Subjects with High-risk Smoldering Multiple Myeloma
This study looks at a new drug called daratumumab to see if it can stop a high-risk precancerous blood condition, called smouldering multiple myeloma, from turning into a more serious cancer. It compares the drug to close observation to see which approach works best.
For: Precancerous form of blood cancer in the bone marrowDenmark · Sweden · Czechia - Ongoing, recruitingTherapeutic confirmatory (Phase III)
A Randomized Phase 3 Study to Evaluate the Efficacy and Safety of Daratumumab in Combination with Cyclophosphamide, Bortezomib and Dexamethasone (CyBorD) Compared With CyBorD Alone in Newly Diagnosed Systemic AL Amyloidosis
This study is looking at a new way to treat AL amyloidosis, a rare condition where unhealthy proteins build up in your body. It compares a new drug called daratumumab with existing treatments to see if it works better and is safe for people newly diagnosed with the condition.
For: AL Amyloidosis (Newly Diagnosed Systemic AL Amyloidosis)Denmark · Italy · Netherlands